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Available online xxxxHopQ is an outer-membrane protein of Helicobacter pylori that binds to human carcinoembryonic antigen-related cell-
adhesion molecules (CEACAMs) with high specificity. We aimed to investigate fluorescence targeting of CEACAM-
expressing colorectal tumors in patient-derived orthotopic xenograft (PDOX)modelswith fluorescently labeled recom-
binant HopQ (rHopQ). Western blotting, flow cytometry and ELISA were performed to determine the efficiency of
rHopQ binding to CEACAMs. rHopQ was conjugated to IR800DyeCW (rHopQ-IR800). Nude mice received orthotopic
implantation of colon cancer tumors. Three weeks later, mice were administered 25 μg or 50 μg HopQ-IR800 and im-
aged 24 or 48 h later. Intravital imageswere analyzed for tumor-to-background ratio (TBR). Flow cytometry and ELISA
demonstrated binding ofHopQ to CEACAM1, 3 and5.Dose-response intravital imaging in PDOXmodels demonstrated
optimal results 48 h after administration of 50 μg rHopQ-IR800 (TBR = 3.576) in our protocol. Orthotopic models
demonstrated clear tumor margins of primary tumors and small regional metastases with a mean TBR = 3.678 (SD
± 1.027). rHopQ showed specific binding to various CEACAMs in PDOX models. rHopQ may be useful for
CEACAM-positive tumor and metastasis detection for pre-surgical diagnosis, intra-operative imaging and
fluorescence-guided surgery.
© 2020 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the
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Cancer is a leading cause of human death worldwide with colorectal
cancer as the third most common cancer and the fourth highest cause of
cancer related mortality, usually due to liver metastasis [1]. Surgical resec-
tion is a conventional part of the treatment plan for patients with colorectal
cancer. In recent years, there has been a transition in surgical management
of colorectal cancer to more minimally invasive techniques, such as laparo-
scopic and robotic platforms,which leads to a loss of tactile feedback for the
surgeon and restricts their field of view.
Despite effective surgical techniques, previous studies have reported a
5.3% rate of radial margin positivity, defined as residual disease at the sur-
gical resection margin [2]. Fluorescence-guided surgery (FGS) can improve
the detection of tumormargins and residual positive disease after resection.
Prior studies in orthotopic colon cancer mouse models have demonstrated
that FGS can improve detection of tumor margins and lead to increased
rates of successful disease-free resection [3–5]. Another cause of progres-
sion of colon cancer is undetected occult metastases.
Previously, carcinoembryonic antigen (CEA) has been identified as an
ideal target for in vivo imaging specifically addressing colorectal tumors
[6]. CEA, also named CEACAM5 or CD66e, is a glycophosphatidyl inositol
(GPI)-anchored cell-surface glycoprotein that has been found to be
overexpressed in the majority of colorectal cancers [7]. CEA belongs to
the carcinoembryonic antigen-related cell-adhesion molecule (CEACAM)
family, which is a member of the immunoglobulin superfamily. CEACAMs
have been considered as reliable biomarkers and targets for a wide variety
of epithelial malignancies, including colorectal cancer [8]. In normal epi-
thelial tissue, most CEACAMs are involved in cell-cell communication and
help to modulate various cellular processes [9,10]. In malignant epithelial
tissue, CEACAMs may play a role in tumorigenesis and the development
of metastases [8].
Recently, it has been shown that Helicobacter pylori (H. pylori) specifi-
cally binds via its outer membrane protein HopQ to human CEACAM1, 3,
5 and 6 [11,12]. TheHopQ-CEACAM interaction seemed to be independent
of calcium as well as pH and indispensable for the translocation of the on-
cogenic effector protein CagA into human host cells [13,14].
We have previously demonstrated that CEACAMs are ideal targets for
imaging of patient-derived orthotopic xenograft (PDOX) nude mouse
models using an anti-CEACAM antibody conjugated to a near infrared
fluorophore [15]. In the present study, we utilized the fluorescence-
labeled recombinant bacterial protein HopQ to test its suitability for fluo-




Cell-culture media andmedia supplements were purchased fromGibco-
Life Technology (Eggenstein, Germany) and the chemicals were obtained
from Sigma (Taufkirchen, Germany), unless stated differently. Hybridoma
secreting the mouse monoclonal antibody (mAb) 6G5j (specific for
human CEACAM1/3/5/6/8) have been recently described [15]. The anti
His mAb 2B6 and isotype matched IgG controls were purchased from
LeukoCom (Germany) and c-Myc tag specific mAb 9E10 was purchased
from AbD Serotec (Germany). Fluorescein isothiocyanate (FITC), phycoer-
ythrin (PE) and horseradish peroxidase (HRP)-coupled secondary goat
anti-mouse IgG F(ab)2 fragments, streptavidin-Cy3 and streptavidin-PE
were obtained from Jackson ImmunoResearch (West Grove, PA).
Recombinant HopQ production
TheHopQ gene fragment, encoding amino acids 22 to 447, was amplified
using genomicDNAprepared fromH. pylori strain P12 (QiagenDNeasy Blood
and Tissue Kit, Hilden, Germany), Taq Platinum polymerase (Invitrogen,
USA) and oligonucleotides that incorporated the restriction site NcoI in the2
sense (5′-gaatagggccatggcggaagacaacggcgtttttttaagcgt-3′) and BamHI in the
and antisense (5 -́acgtatggatccagggttgttgccaagttcttgaataag- 3′) primer. The
column-purified PCR-product was digested with NcoI and BamHI, gel-
purified, and cloned into the appropriately digested plasmid pOPE101
(Genbank #Y14585). The expression cassette consists of a pelB leader, the
truncated HopQ22-447 sequence which is followed by c-Myc- and a (His)6-
tag sequence.
The plasmid was transformed into E. coli XL10 Gold (Stratagene, USA)
and transformants were selected for on LB agar plates containing 100 μg/
ml carbenicillin, 12.5 μg/ml tetracycline and 0.1 M glucose as a repressor.
For expression, an overnight culture in selective LB medium (100 μg/ml
carbenicillin, 12.5 μg/ml tetracycline and 0.1 M glucose) was diluted in
freshly prepared analogous selective medium and grown at 37 °C until an
optical density (at 600 nm) of 0.6 was reached, after which protein expres-
sion was induced by the addition of IPTG to a final concentration of 75 μM.
After 12 h induction at 24 °C (230 rpm), the proteins were harvested from
the periplasmatic space as described [16]. Briefly, the pelleted bacteria
were resuspended in 1/16 culture volume of cold spheroblast solution
(50 mM Tris-HCl pH= 8.0, 20% sucrose, 1 mM EDTA) and gently shaken
for 1 h at 4 °C. The suspensionwas centrifuged at 30,000 g for 1 h at 4 °C and
the supernatant, representing the periplasmatic extract, was dialyzed twice
overnight against 5 l of PBS at 4 °C. The solution was passed through a 0.45
μm filter and adjusted to 0.5 MNaCl and 20mM imidazole for loading on a
Ni-NTA FPLC-column (GE-Healthcare, USA). The (His)6-tagged proteinwas
eluted with elution buffer (PBS adjusted to 0.5 M NaCl and 0.5 M imidaz-
ole). Protein-containing fractions were dialyzed twice overnight against
2 l of PBS at 4 °C. rHopQ aliquots were adjusted to 1 mg/ml with PBS
and stored at −80 °C. Purity and integrity of the protein was confirmed
by Coomassie-gel staining and immunoblot using the c-Myc tag specific
mAb 9E10. The expected molecular weight of the processed rHopQ is
47.8 kDa, including the tags.
Cell culture
The epithelial cell lines LS174T (human colon carcinoma), MKN45 (gas-
tric carcinoma), HT29, Caco-2 (colon carcinoma) and A549 (lung carcinoma)
cancer cell lines (American Type Culture Collection.Manassas, VA) all endog-
enously expressing CEACAM1, CEACAM5 and CEACAM6 were cultured in
DMEM (GIBCO) supplemented with 10% (v/v) heat inactivated fetal calf
serum (FCS) and 4 mM L-glutamine at 37 °C in a humidified atmosphere
with 5% CO2. For the experiments in the present study, cells were used at
tight confluency due to highest CEACAM expression as previously shown
[17]. Chinese-hamster ovary (CHO) transfectants were cultured in DMEM
(GIBCO,USA) supplementedwith 1mg/mlG418, 10% (v/v) heat inactivated
FCS and 4 mM L-glutamine. In all cases, cell viability was tested before use
and found to be over 90% as measured by trypan blue exclusion.
Fluorophore conjugation
Coupling of rHopQ to phycoerythrin (PE) was performed with the
lightning-link rapid PE labeling kit (Expedeon/Abcam, Berlin, Germany),
to DL488 using the Lightning-Link® Rapid DyLight 488 Antibody Labeling
Kit (Novus Biological), to biotin with the Mix-n-Stain biotin antibody label-
ing kit (Sigma) and for IR800with the IR800DyeCW (IR800) NHS ester sys-
tem (LI-COR Biosciences Inc., Lincoln, NE) according to the manufacturer's
protocol. rHopQ-IR800 was incubated on a rotator plate (Fisher Scientific,
Hampton, NH) under basic conditions at room temperature for 2 h. Gel
desalting columns (Thermo Fisher Scientific, Waltham, MA) were used
for removal of unbound dye by adding the mixture and centrifuging three
times at 2115 g for 3 min. After centrifugation, the rHopQ-IR800 flow-
through was removed from the column and stored at 4 °C until further use.
Direct enzyme-linked immunosorbent assay (ELISA)
Direct ELISA was performed with indicated cell lysates dispensed at 100
μl per well in 96-well microplates (Nunc MaxiSorp) in triplicates. After
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(BSA/PBS), wells were incubated with 100 μl of 5 μg/ml rHopQ diluted in
1% BSA/PBS, washed 3 times with PBS and labeled with 100 μl anti-His
mAb 2B6 (5 μg/ml). Control staining samples were incubated with mAb
6G5j or isotype matched control (5 μg/ml). Wells were then washed three
times with PBS and incubated with horse-radise peroxidase (HRP)-coupled
goat anti-mouse antibody (Jackson ImmunoResearch Lab Inc., West Grove,
PA). After washing, staining was developed with 100 μl/well
tetramethylbenzidine solution (TMB Xtra, EcoTrak). The enzymatic reaction
was stopped with 200 mM H2SO4 solution and absorbance was measured at
450 nm in a microtiter plate reader (Sunrise, Tecan).
Flow cytometry
Indicated cell typeswere labeledwith rHopQ-DL488 (10 μg/ml in 1,25 di-
lution) or mAb 6G5j (10 μg/ml) diluted in 3% FCS/DMEM for 1 h, washed
with 3% FCS/DMEM. For the mAb - labeling incubation was with FITC con-
jugated goat anti-mouse F(ab′)2 antibody (Jackson ImmunoResearch Lab
Inc., West Grove, PA) diluted 1:50 in 3% FCS/DMEM. Background fluores-
cence was determined using isotype matched Ig. The stained cell samples
were analyzed in a FACScalibur flow cytometer (Becton Dickinson, Franklin
Lakes, NJ) and the data were processed utilizing CellQuest software (Becton
Dickinson, Franklin Lakes, NJ). Where applicable, dead cells, identified by PI
staining (5 μg/ml), were excluded from the determination.
To determine the dose-response of rHopQ, rHopQ-biotin and rHopQ-PE
we incubated 100.000 CHO-CEACAM1 cells were incubated with 5, 10 and
20 μg/ml of rHopQ, rHopQ-biotin and rHopQ-PE, respectively. Subsequently,
the rHopQ-biotin was labeled with Streptavidin-PE, the rHopQ with anti His
mAb 2B6 (10 μg/ml) followed by goat anti mouse pAb-PE (1,50). Samples
were analyzed in a FACScalibur flow cytometer (Becton Dickinson).
Immunofluorescence (IF)
Serial sections of 4 μm were prepared from 4% paraffin-embedded
human jejunum tissues, previously fixed in neutrally buffered formalin,
mounted on 3-aminopropyltriethoxysilane-coated slides and were then
demasked, by incubation for 10 min at 95 °C in citrate buffer pH 6. Endoge-
nous peroxidase activity was blocked by treatment with 3% H2O2 for 5 min
and subsequent washing with PBS. HT29 cells grown on cover slips were
fixed similarly. Cells on cover slips and tissue sections were then blocked
with 1% BSA/PBS and stained with 10 μg/ml rHopQ-biotin followed either
by Cy-3- (IF) coupled streptavidin (Jackson ImmunoResearch Lab Inc., West
Grove, PA). The samples were washed after each staining step with cold
PBS three times. HRP-staining was developed with 3,3-diaminobenzidine
(DAB, brown precipitate) and the reaction was stopped by several washes
with PBS. Stained tissue sections were mounted and documented by micros-
copy. Fluorescence staining was analyzed with the Leica DMI4000B
microscope.
Western blotting
Indicated cell-lines were lysed in RIPA-based lysis buffer containing
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate supplemented with protease inhibitor cocktail set III
(Calbiochem, San Diego, CA) and PhosSTOP phosphatase inhibitor cocktail
(Roche, Basel Switzerland) and incubated on ice for 30 min. Lysates were
centrifuged at 10,000g and 4 °C for 15 min. Approximately 50 μg of total
proteinwas subjected to SDS-PAGE, blotted onto nitrocellulose membranes
(Schleicher & Schuell, Dassel, Germany) and reacted with 10 μg/ml mAb
6G5j (positive control), 10 μg/ml isotype control mAb and 10 μg/ml
rHopQ followed by anti-His mAb 2B6, respectively. After washing, HRP-
coupled goat anti mouse pAb was added and subsequently detected with
an ECL chemiluminescence substrate and monitored by the LAS3000 gel
documentation system (Fuji, USA). The loading control with β-actin was
detected by HRP-coupled mouse anti β-actin according to the manufactur-
er's protocol (Sigma Aldrich, A3854).3
Binding kinetics (IC50)
To determine the binding kinetics of anti-CEACAM antibody 6G5j com-
pared to rHopQ, recombinant CC1-Fc or CC1-V-Fc comprising the entire ex-
tracellular domain, or only the variable region respectively of human
CEACAM1, were expressed as human IgG1 Fc-fusion proteins in 293 HEK
cells. Purified proteins were coated on a Nunc ELISA plate (Maxisorp,
#439454, ThermoScientific, USA) at 500 ng/well (over-night at 4 °C in
0.1 M Na2CO3 buffer pH 9.6) and blocked with 2% Milk-PBS (1 h at RT).
Serial dilutions of the 6G5j antibody or the HopQ protein were incubated
over-night at 4 °C. Bound antibody was detected with an HRP-conjugated
polyclonal goat anti-mouse antibody (DAKO,P0447) whereas the bound
HopQ was detected with a biotinylated anti-myc antibody (#9E10, Abd
Serotec, for 2 h at RT), followed byHRP-conjugated Streptavidin (RocheDi-
agnostics GmbH, REF 11089153001, 30 min at RT). The TMB-color forma-
tion was blocked by addition of H2SO4 (after approximately 30 s), and
absorbance measured at 450 nm. The ELISA plate was washed three
times with T-PBS after each incubation step. For calculation of the IC50,
the concentration sufficient to obtain 50% saturation, the maximum and
minimal values were set to 100 and 0% respectively and a non-linear re-
gression was modelled (Prism 7, GraphPad, USA). The option “inhibitor
versus normalized response” with a variable slope was chosen for the
IC50 calculation.
Animals
Female and male nude mice (nu/nu) age 4–6 weeks were purchased
from The Jackson Laboratory (Bar Harbor, ME). Mice were housed in a bio-
safety room and fed an autoclaved standard mouse diet. For surgical proce-
dures, micewere anesthetizedwith an intraperitoneal injection of xylazine,
ketamine and PBS. Post-procedural pain was treated with subcutaneous
buprenorphine. At the conclusion of the experiments, mice were eutha-
nized by CO2 inhalation followed by cervical dislocation. Studies were ap-
proved by the San Diego Veterans Administration Medical Center
Institutional Animal Care and Use Committee (IACUC, animal use protocol
A17-020).
Establishment of subcutaneous colon cancer cell-line tumors in nude mice
Nude mice (n= 2) were administered inhaled isoflurane and the flank
was prepped with 70% ethanol solution. Under sterile conditions, LS174T
cells (1 × 106, American Type Culture Collection, Manassas, VA)
reconstituted in 50 μL Matrigel Matrix (Corning Life Sciences, Corning,
NY) and 50 μL cold PBS were injected into the bilateral flanks subcutane-
ously. Tumors grew until they were approximately 5 mm in diameter in
nudemice. Tumorswere resected and divided into 1mm fragments for sub-
sequent orthotopic implantation, as described below.
Establishment of colon cancer orthotopic models
Patient-derived tumors were chosen based on previously published data
demonstrating over-expression of CEACAM in C4 and Lung 4 tumor lysates
(C4 = surgically-resected patient primary colon cancer and Lung 4 = sur-
gically resected colon cancer lungmetastasis) [15]. Lung 4 and C4 cell-lines
represent patient-derived colon tumors obtained at our institution under
IRB protocol 140,046 with informed patient consent and established in
nude mice as transplantable tumors.
For orthotopic implantation, nude mice (n=11) were administered in-
traperitoneal ketamine cocktail to induce anesthesia. The abdomen was
sterilized with a 70% ethanol solution. A small incision was made in the
midline through the skin and peritoneum. The cecum was carefully identi-
fied. A 2 mm fragment of tumor, previously grown subcutaneously in nude
mouse models was implanted onto the serosa of the cecum using an 8–0
nylon suture (Ethicon Inc., Sommerville, NJ). Four mice received
orthotopic implantation of a Lung 4 tumor fragment to determine appropri-
ate dose and time of imaging, as described below. Six mice received
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described below. One mouse received orthotopic implantation of a C4
tumor fragment, to confirm efficacy in PDOX mouse models. The perito-
neum and skin were closed with a 6–0 nylon suture (Ethicon Inc.,
Sommerville, NJ). Tumors grew until palpable, or approximately 5 mm in
diameter [18,19].
Fluorescence imaging
Once tumor growth was sufficient as defined, Lung 4 PDOX mice (n =
4) were administered 25 μg or 50 μg, respectively, of rHopQ-IR800,
reconstituted in PBS, via tail vein injection. Mice were imaged 24 or 48 h
after administration. Prior to imaging, mice were administered intraperito-
neal anesthesia and the cecum was surgically exposed. Imaging was per-
formed on the LI-COR Pearl Trilogy Small Animal Imaging System (LI-
COR, Lincoln, NE), which is equipped for fluorescent imaging at 700 and
800 nm. Once an appropriate dose and time of imaging was determined,
orthotopic cell-line models (n = 6), and an additional C4 PDOX models
were imaged 48 h after administration of 50 μg of rHopQ-IR800
reconstituted in PBS via tail vein injection, in order to confirm that these
conditions could brightly visualize the tumor.
Statistical analysis
The tumor to background ratio (TBR) was calculated as the maximum
tumor fluorescence signal divided by maximum background fluorescent
signal under the conditions used. Background was set as the surrounding
intra-abdominal organs, mainly small bowel. Fluorescence signals were
quantified with automated areas generated with the Image Studio Soft-
ware, with a consistent standard deviation from background signal of 10
andminimumof 250 pixels per area. Mean TBRwas calculated for mice im-
aged 48 h after administration of 50 μg of rHopQ-IR800 using SPSS version
24 (IBM, Armonk, NY).Fig. 1. Recombinant HopQ binding properties. (a) Flow cytometric analyses of rHo
endogenously CEACAM-expressing cell-lines. rHopQ and positive control mAb stainin
(b) ELISA analyzed lysates were immobilized and bound to rHopQ followed by mouse a
(white bars), followed by incubation with HRP-coupled secondary antibody and TMB s
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Results
Flow cytometric analyses using CHO-cell transfectants expressing either
human CEACAM1, 3, 4, 5, 6, 7 and 8 demonstrated binding of rHopQ-PE to
CEACAM 1, 3 and 5 (Fig. 1a). Isotype matched IgG and 6G5j as CEACAM
binding monoclonal antibody (mAb) were used as negative and positive
controls, respectively. rHopQ binding to human CEACAM 1, 3 and 5 was
confirmed by ELISA. Indicated CHO transfectant lysates were immobilized
and detected by rHopQ followed by anti-His mAb 2B6 detection or mAb
6G5j staining as positive control (Fig. 1b). Western blotting demonstrated
that rHopQ detected endogenously expressed CEACAM1 with a molecular
weight of approximately 120 kDa and CEACAM5 with a molecular weight
of approximately 180 kDa in lysates of epithelial cell lines derived from gas-
tric (MKN45), colon (HT29, Caco-2) and alveolar (A549) cancer cell lines
(Fig. 2). Additionally, rHopQ bound to lysates of CHO cells expressing
CEACAM1 and 5 (Fig. 2a).
Next, we analyzed the performance of rHopQ-PE by immunohistochem-
ical staining (IHS) utilizing 4% PFA fixed HT29 cells (Fig. 2c) and sections
of human jejunal tissue (Fig. 2d) and rHopQ-PE binding was similar to pre-
vious findings using anti-CEACAM antibody 6G5j [15]. In order to estimate
the affinity of rHopQ against CEACAM1, we determined the IC50 against
two eukaryotically expressed CEACAM1-Fc fusion proteins, as indicated
by the concentration resulting in 50% maximal binding. The IC50 of
HopQagainst the CEACAM1-Fc fusion protein containing the full-length ex-
tracellular domain or the V-region only was 2.5 and 1.7 nM respectively.
This high affinity is found to be in the same range as obtained for the pos-
itive control antibody 6G5j (2.3 and 2.4 nM, respectively) that had been
previously used for tumor detection (Fig. 3) [15].
Dose-response intravital imaging of colon cancer PDOXmodels (n=4)
of Lung 4 after administration of 25 μg rHopQ-IR800 demonstrated a low
TBR 24 and 48 h after administration (TBR = 0.901 and 1.220, respec-
tively) (Fig. 4a, b). After administration of 50 μg rHopQ-IR800, PDOX
models of Lung 4 imaged 24 h later had a TBR = 1.781 (Fig. 4c). 48 hpQ-PE binding to CHO transfectants expressing indicated human CEACAMs and
g are shown with a black line, negative control staining is shown with a grey line.
nti-His mAb 2B6 (LeukoCom, Germany, grey bars) or positive control mAb staining
ubstrate for staining. Data are representative of three independent experiments.
Fig. 2.Western blotting, fluorescence staining and immunohistochemistry of recombinant HopQ binding to CEACAM1, CEACAM5, and endogenously expressed CEACAMs.
(a) Western blot analysis of the rHopQ (A) and mAb 6G5j (b) binding to lysates originated from CHO-CEACAM1, CHO-CEACAM5, gastric (MKN45), colon (HT29, Caco-2)
and alveolar (A549) cancer cell lines as detected by chemiluminescence. Beta actin staining was utilized to control proper loading of samples. Representative data from two
separate experiments are shown. (c) Fluorescence staining of paraffin-embedded HT29 cells labeled with 10 μg/ml HopQ-PE. (d) Immunohistochemistry of paraffin-
embedded human jejunum tissue labeled with 10 μg/ml of biotinylated HopQ followed by Cy3-coupled streptavidin. Scale bars represent 100 μm.
H.M. Hollandsworth et al. Translational Oncology 13 (2020) 100857after administration of 50 μg rHopQ-IR800, imaging demonstrated a TBR
= 3.576, the highest TBR observed (Fig. 4d). Small tumors <2 mm in di-
ameter, otherwise invisible, were readily imagedwithminimal background
signal (Fig. 4c). Visualization was confirmed with another colon cancer
PDOX model (C4) with TBR = 3.977, 48 h after administration of 50 μg
rHopQ-IR800 (Fig. 5).
Orthotopic colon cancer cell-linemodels (n=6)were imaged 48 h after
administration of 50 μg rHopQ-IR800. Tumormargins were distinctly iden-
tified with a mean TBR = 3.678 (SD ± 1.027). The LS174T orthotopic
colon cancer cell-line model developed regional metastases that measured
approximately 2 mm in diameter, which were also distinctly viewed with
fluorescence imaging, which were otherwise invisible (Fig. 6).Fig. 3. Recombinant HopQ protein (a) or the antibody 6G5j (b) were incubated in se
concentration sufficient to obtain half-maximum binding (IC50) was calculated by usag
the CC1-Fc and 1.7 nM against the CC1-V-Fc protein respectively (a). Likewise, the 6G
(b). The non-linear regression curves are depicted in color.
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Discussion
For the first time, we show in the present report that a bacterial adhe-
sion protein can potentially be utilized for detecting metastatic colorectal
cancer in a clinically relevant PDOX mouse model. Recombinant HopQ-
IR800 specifically binds to CEACAM1 and 5 for near-infrared fluorescence
visualization of orthotopic cell-line and PDOX mouse models of colon can-
cer. The results of the present study are consistent with our previous find-
ings that CEACAMs are ideal targets for in vivo fluorescence imaging of
colon cancer, as demonstrated in our PDOX mouse models with an anti-
CEACAM antibody-fluorophore conjugate [15]. Important to note, rHopQ
binds to CEACAM1 [13] even when coupled with diverse fluorochromesrial dilutions on ELISA-plate coated with CC1-Fc and CC1-V-Fc respectively. The
e of a non-linear regression fit. The HopQ demonstrated an IC50 of 2.5 nM against
5j antibody showed an almost identical IC50 of 2.4 (2.3) nM against both proteins
Fig. 4. Dose-response fluorescence imaging of the Lung 4 PDOX model demonstrates distinct tumor margins of tumors <2 mm in diameter. (a) Imaged 24 h after
administration of 25 μg rHopQ-IR800, TBR = 0.901. (b) Imaged 48 h after administration of 25 μg rHopQ-IR800, TBR = 1.220. (c) Imaged 24 h after administration of
50 μg rHopQ-IR800, TBR = 1.781. (d) Imaged 48 h after administration of 50 μg rHopQ-IR800, TBR = 3.576.
H.M. Hollandsworth et al. Translational Oncology 13 (2020) 100857or biotin. Therefore, rHopQ can be used for a wide variety of applications
including flow cytometry, ELISA, western blotting and immunohistochem-
ical approaches. Of the conditions tested, imaging at 48 h gave the best
tumor-to-background ratio. In contrast to glycosylated antibodies, rHopQ
is a bacterial protein without glycosylation protecting it from degradation.
Although rHopQ has been demonstrated in previous literature to bind
CEACAM1, 3, 5 and 6 [11,12], we were puzzled that we did not observe
CEACAM6 interaction. However, it may be that HopQ has a higher affinity
to CEACAM1, 3 and 5 whereas the interaction with CEACAM6 has low af-
finity. Further analyses need to be done to clarify this hypothesis.
CEACAM's have been demonstrated to be a useful target for
fluorescence-guided surgery. While anti-CEACAM antibody 6G5j-IR800
has been demonstrated to have a TBR of 3.17 [15], in the present study
we found that rHop-IR800 has a mean TBR of 3.678. When compared to
previously published data on anti-CEACAM antibody 6G5j [15], which
has a molecular weight of 150 kDa, rHopQ has a molecular weight of
47 kDa, which may allow rHopQ to be more efficiently delivered to its tar-
get than the larger antibody. Future studies will be performed to directly
compare the properties of 6G5J-IR800 and rHopQ-IR800 in orthotopic
mouse models of colon cancer.
Previously, it has been shown that fluorescence-guided surgery (FGS) is
effective for achieving complete tumor resection and decreasing tumorFig. 5. Fluorescence imaging of the C4 PDOX model 48 h aft
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recurrence rates in orthotopic mouse models [3,4]. The present study dem-
onstrates that rHopQ-IR800 was able to detect small primary tumors and
metastases, which is promising for possible effective FGS. Further studies
are needed to confirm this hypothesis. In addition to primary colon cancer,
fluorescence imaging may be useful for imaging of colorectal metastases.
Small hepatic metastases are often difficult to identify on pre-operative im-
aging or with intra-operative imaging and can significantly worsen progno-
sis [20]. A previous study demonstrated that fluorescence imaging can
improve detection and resection of colon cancer-derived hepaticmetastases
[21,22]. The present study shows that rHopQ-IR800 is effective for imaging
of occult colorectal cancer metastases.
In the present study, orthotopic colon cancer cell-line tumors and two
colon cancer PDOX models, one from a primary patient tumor and the
other from a metastatic tumor, were fluorescently visualized with rHopQ-
IR800, which is promising for successful transition into the heterogeneous
clinical setting. The present study emphasizes the importance of orthotopic
mouse models in providing clinically relevant models of cancer.
Limitations of this study include a small sample size of mouse models.
Further studies will be performed with additional liver metastases models
to confirm the efficacy of rHopQ-IR800 at identifying hepatic metastases
in a PDOX mouse model. The new book, “Strategies for Curative
Fluorescence-Guided Surgery,” edited by Hoffman and Bouvet [23] defineser administration of 50 μg rHopQ-IR800, TBR = 3.977.
Fig. 6. Representative image of orthotopic colon cancer cell-line (LS174T) model, 48 h after administration of 50 μg rHopQ-IR800. Primary tumor and regional metastases
margins are distinctly viewed. Mean TBR = 3.678 (SD ± 1.027), n = 6.
H.M. Hollandsworth et al. Translational Oncology 13 (2020) 100857numerous fluorescent probes that were demonstrated to clearly define
tumor borders in various mouse models of cancer as well as in the clinic.
To date, there are eight antibody-fluorescent probes in clinical develop-
ment for various cancer types and one protein based fluorescent probe in
clinical development [24]. Prior to translation in the clinic, rHopQ-IR800
will require safety and efficacy testing in human cancer patients. Another
limitation to this study is that rHopQ is targeted to human tumors, not mu-
rine tissues, which can result in artificially elevated TBR. In addition, the
ability of rHopQ to bind to multiple CEACAMs may lead to binding of nor-
mal tissue in addition to tumor, whichmay lead to lower TBR. Further stud-
ies need to be performed to assess the efficacy of rHopQ to visualize
primary and metastatic human colon cancer.
The present study demonstrates high affinity binding of rHopQ to epi-
thelial cancers overexpressing CEACAM, including colon, gastric and lung
cancer. Recombinant HopQ enabled fluorescence imaging provides a dis-
tinct tumor margins of primary tumors and metastases in PDOX and
orthotopic cell-line mouse models of colon cancer. rHopQ may be a useful
alternative to CEACAM-specific antibodies for pre-surgical diagnosis,
intra-operative imaging and fluorescence-guided surgery (FGS) in epithe-
lial malignancies that overexpress various CEACAMs. The potential advan-
tages of rHopQ over antibody-based imaging probes include lower
molecular weight which may lead to improved delivery of the fluorescent
probe. Future studies will determine the clinical potential of rHopQ.
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